Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07UHS
|
|||
| Former ID |
DCL000804
|
|||
| Drug Name |
Fingolimod
|
|||
| Synonyms |
2-Amino-2-(4-octylphenethyl)propane-1,3-diol
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Primary progressive multiple sclerosis [ICD-11: 8A40.1; ICD-9: 340] | Approved | [1], [2] | |
| Company |
Novartis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H33NO2
|
|||
| Canonical SMILES |
CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N
|
|||
| InChI |
1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3
|
|||
| InChIKey |
KKGQTZUTZRNORY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 162359-55-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980354, 10627340, 11538030, 14800795, 44436888, 50070757, 52231945, 91613352, 103298437, 104045114, 104380165, 112629137, 124899206, 125335078, 126522750, 126659901, 126665797, 128394615, 134339282, 135204658, 135626722, 135650261, 137003753, 140236536, 152344348, 160820803, 162221744, 163091250, 163838506, 164834614, 174006739, 175268765, 175426965, 175427125, 184527777, 204414213, 210274752, 210280385, 223660888, 223770775, 226398832, 242078815, 249836440, 251873579, 251916753, 251917992, 252214240, 252433026, 252478872
|
|||
| ChEBI ID |
CHEBI:63115
|
|||
| ADReCS Drug ID | BADD_D02464 | |||
| SuperDrug ATC ID |
L04AA27
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sphingosine-1-phosphate receptor 1 (S1PR1) | Target Info | Modulator | [2], [3] |
| KEGG Pathway | FoxO signaling pathway | |||
| Sphingolipid signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Fc-epsilon receptor I signaling in mast cells | |||
| S1P3 pathway | ||||
| S1P1 pathway | ||||
| Sphingosine 1-phosphate (S1P) pathway | ||||
| PDGFR-beta signaling pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Lysosphingolipid and LPA receptors | ||||
| WikiPathways | Signal Transduction of S1P Receptor | |||
| Small Ligand GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2407). | |||
| REF 2 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||
| REF 3 | Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs. 2008 Sep;13(3):465-77. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.